July 18 Company Quick Takes: Mallinckrodt, Silence in RNAi deal; plus Pear, Blueprint and more
Mallinckrodt licenses RNAi candidate from Silence
Mallinckrodt plc (NYSE:MNK) obtained an exclusive, worldwide license to C3-targeted RNAi therapy SLN500 from Silence Therapeutics plc (LSE:SLN), plus options to license up to two additional complement-targeted preclinical candidates. Silence will receive $20 million up front and is eligible for up to $673 million in research, clinical, regulatory and commercial milestones for SLN500, plus tiered, low double-digit to high-teen royalties; the biotech is also eligible for up to $713 million for each additional candidate that Mallinckrodt opts into. Silence will be responsible for development of each asset through Phase I, after which Mallinckrodt would assume clinical and commercial responsibility.
Pear seeking approval of digital insomnia, depression therapeutic
Pear Therapeutics Inc. (Boston, Mass.) submitted an application to FDA for Somryst, a prescription digital therapeutic to treat chronic insomnia and depression, via the agency's software precertification pilot program...